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Title	25 
Review of the evidence of lymphedema treatment effect 26 
Abstract	27 
Lymphedema treatment aims to alleviate symptoms, prevent progression and reduce risk of 28 
skin infection. Mainstream treatment options have been investigated in over 160 studies. 29 
Findings from these studies have been included in at least one of more than 20 literature 30 
reviews. A critique of these reviews was undertaken to summarise efficacy findings. The 31 
quality of the reviews was evaluated and gaps in the research identified, to better guide 32 
clinical practice. Overall, there was wide variation in review methods. The quality of studies 33 
included in reviews, in terms of study design and reporting overall has been poor. Reviews 34 
consistently concluded that complex physical therapy is effective at reducing limb volume. 35 
Volume reductions were also reported following the use of compression garments, pumps 36 
and manual lymphatic drainage. However, greatest improvements were reported when these 37 
treatments formed a combined treatment program. Large, well-designed, evaluated and 38 
reported randomised, controlled trials are needed to evaluate and compare treatments. 39 
Consistent outcome measures will allow better quality reviews and meta-analysis in the 40 
future.  41 
Key	words	42 
Lymphedema, therapy, review, compression bandages 43 
Introduction	44 
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Lymphedema is a condition characterised by excess accumulation of protein-rich tissue fluid 45 
in interstitial spaces1. Impairment of the lymphatic system reduces the capacity to transport 46 
macromolecules including protein back in to the blood vascular system, resulting in swelling 47 
and a range of other physical symptoms (e.g., heaviness, tightness, tingling, pain)1–3. Primary 48 
lymphedema develops as a result of an inherited abnormality of the lymphatic system, while 49 
secondary lymphedema occurs following trauma or injury4. Secondary lymphedema is most 50 
commonly associated with lymphatic filariasis in developing countries and cancer in 51 
developed countries4,5.  52 
Secondary lymphedema is considered a progressive and incurable disease, requiring ongoing 53 
attention, self-management and long-term treatment 6–8. Early detection and initiation of 54 
treatment have been associated with better long term outcomes 9. Without appropriate 55 
management, lymphedema may progress and result in serious complications including skin 56 
infections, reduced immunity and impaired mobility 10. Currently, there is no cure for 57 
lymphedema, and as such, treatment strategies aim to reduce swelling, prevent progression, 58 
reduce risk of infection and alleviate associated symptoms 11. Treatments which lead to 59 
improved symptoms have been shown to reduce the impact of lymphedema on daily 60 
activities, self-image and quality of life 12. 61 
A range of conservative treatments are commonly prescribed by health professionals to treat 62 
lymphedema, including complex physical therapy (CPT), manual lymphatic drainage (MLD), 63 
compression (bandages, garments and pumps), low-level laser therapy or exercises 13. When 64 
pitting lymphedema is present, characterised by increased interstitial fluid and low 65 
responsiveness when the tissue is compressed, surgery may be considered 14,15. The efficacy 66 
of these treatments have been collectively studied and reported in over 160 peer-reviewed 67 
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publications, most of which (n =168) have been included in at least one of more than 20 68 
lymphedema treatment reviews.  69 
Despite this vast body of work, consensus regarding who may benefit from which treatment 70 
is lacking and contributes to inconsistent guidelines 16–18. Clinical practice guidelines aim to 71 
improve the delivery of health care and health outcomes, while avoiding use of ineffective or 72 
harmful treatments or therapies 19.  The process of developing such guidelines requires 73 
systematic identification, appraisal and synthesis of the relevant literature. Importantly, only 74 
when strength of the evidence is evaluated and considered should findings from reviews be 75 
used to inform treatment guidelines and clinical practice 19. The strength of evidence used to 76 
inform clinical guidelines is dependent on the appropriateness of study designs to answer 77 
specific research questions, the methods used to avoid and minimise bias which could 78 
influence research findings, and statistic precision (i.e., how likely it is that the results are real 79 
and not due to chance) 20. The purpose of this work was to critique lymphedema treatment 80 
reviews and in doing so, to identify the extent to which the body of research should be used 81 
to guide clinical practice.  It was also an objective to highlight priorities for future 82 
lymphedema treatment research.  83 
Methods	84 
Literature search 85 
The reviews were identified through searches conducted in Medline, Pubmed, CINAHL, and 86 
Cochrane Database of Systematic Reviews. The main search terms were “lymphoedema or 87 
lymphedema”, “treatment or therapy” and “systematic review or literature review or meta-88 
analysis”. Additional search terms included specific treatment strategies “complex physical 89 
therapy, complex decongestive therapy, manual lymph drainage, laser therapy, compression, 90 
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surgery, massage, pneumatic pump, exercise” to ensure reviews assessing one particular 91 
lymphedema treatment strategy only, were identified. In addition, internet searches were 92 
undertaken to identify any reviews commissioned by government and/or lymphedema 93 
organisations but not published in journals, and therefore unavailable through electronic 94 
databases. The abstracts of 206 manuscripts were reviewed against the criteria below and the 95 
full text versions of 34 potentially suitable reviews were retrieved.  96 
Inclusion criteria 97 
Reviews were included if they met the following inclusion criteria: 98 
 A focus of the review was the effect of lymphedema treatment 99 
 Electronic literature searches were conducted as part of identifying relevant studies 100 
included  in the review 101 
 Inclusion and exclusion criteria were defined and reported 102 
 A method of assessing the methodological quality of included studies was 103 
described and applied. 104 
Assessment of methodological quality 105 
Reviews were assessed against methodological quality criteria to evaluate rigour. The 106 
Cochrane Collaboration provides a tool for assessing risk of bias in the design and execution 107 
of randomised, controlled trials (RCTs) 21. The tool specifies factors that should be 108 
considered to assess the risk of selection (sequence generation and allocation sequence 109 
concealment), performance (blinding of participants and personnel), detection (blinding of 110 
outcome assessment), attrition (incomplete outcome data), and reporting (selective outcome 111 
reporting) biases, as well as other potential sources of bias (any bias not assessed in other 112 
domains).  113 
7 
 
There were several tools specified in the reviews to assess the methodological quality of 114 
observational studies, focusing on different strengths and weaknesses of study design. In 115 
order to critique the methods, results and conclusions of these reviews, they were assessed for 116 
their consideration of a number of factors relating to review protocol. Reviews were scored as 117 
meeting the criteria if the review authors had considered each factor, for example, 118 
randomisation, in their assessment of the quality of the evidence, regardless of whether the 119 
participants in the original studies were randomised. These factors, and the reasons for their 120 
importance in reviewing the quality of available evidence, are described below: 121 
 study eligibility criteria – consideration of the inclusion and exclusion criteria and 122 
the influence these have on representativeness of the sample and generalisability of 123 
results;  124 
 randomisation procedures (for RCTs) – identification of randomisation procedures, 125 
whether or not randomisation was successful, and whether there were any 126 
systematic differences between study groups at baseline; 127 
 methods for measuring lymphedema – identification of the methods used to 128 
measure lymphedema (e.g., water displacement method to measure limb volume), 129 
and the impact of different methods on the appropriateness of comparing results 130 
between studies; 131 
 adequate description of interventions – identification of treatment protocol and 132 
consideration of the impact of different protocols on results; 133 
 follow-up periods – ability to determine whether positive results were maintained 134 
over time, as well as identifying adverse effects; 135 
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 details of patients lost to follow up – reasons for drop-outs and any differences 136 
between those who completed the intervention and those who withdrew from the 137 
study; 138 
 statistical pooling (meta-analysis) – consideration of heterogeneity in study design 139 
and appropriateness of combining results. 140 
Results	141 
Twenty two reviews met the inclusion criteria outlined above, with twelve excluded because 142 
they did not focus on lymphedema treatment effect or did not adequately describe inclusion 143 
criteria or criteria to assess methodological quality. One review paper 3 was a focused 144 
summary of findings from a more extensive review undertaken by Oremus et al. 22. The full 145 
review was included rather than the summary, leaving 21 reviews included in this critique. 146 
Twenty reviews focussed on mainstream treatment types, while one review concentrated on 147 
self-management strategies23. Eleven reviews included studies of a range of lymphedema 148 
treatment strategies. The remaining ten reviews were single-focus, with three reviewing 149 
pneumatic compression 24–26, two reviewing low level laser therapy 27,28, two reviewing 150 
surgical techniques 29,30 and one reviewing the use of manual lymphatic drainage 31, exercise 151 
32, or benzopyrones 33 to treat lymphedema. The 21 reviews were published between 1998 152 
and 2014 and included discussion of 168 primary studies of lymphedema treatment, 153 
published between 1966 and 2013. No steps were taken to attempt to remove duplicates of 154 
original studies from reviews. We evaluated whether the different reviewers including the 155 
same original studies came to different conclusions if they had used different review 156 
protocols. As indicated in key findings, the conclusions about the effect of each treatment did 157 
not differ significantly, regardless of which review protocol had been used. An overview of 158 
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each review’s characteristics, including eligibility criteria and methods for assessing study 159 
quality, is presented in Table 1. 160 
Methodological	quality	of	reviews	161 
 162 
The reviews’ methods were assessed against the criteria described above (see Assessment of 163 
methodological quality). Consideration of these factors by reviewers is summarised in Table 164 
2 (Cochrane criteria for assessing quality of RCTs) and Table 3 (additional criteria applicable 165 
to all study designs). Only one of the 21 reviews, a Cochrane Systematic Review, assessed 166 
studies against all of the above criteria10, and reported the authors’ judgement of risk of bias 167 
for individual studies. Another Cochrane Systematic Review 33 appeared to assess studies for 168 
risk of selection, performance, detection and attrition bias, detailing randomisation and 169 
blinding processes, and describing reasons for participant withdrawals. However, the 170 
possibility of selective outcome reporting was not discussed, and the reviewers did not make 171 
any explicit judgement of risk of bias in individual studies. A further eight reviews limited 172 
study inclusion to RCTs or non-randomised experimental trials 26–28,31,34–37. Of these, seven 173 
considered the impact of randomisation processes, blinding and attrition on the risk of bias in 174 
included studies 26–28,31,35–37, and considered these factors when reporting results. The 175 
remaining eleven reviews included observational as well as experimental studies. Reviews 176 
taking important aspects of study design into account (see Table 3) when reflecting on study 177 
results and forming conclusions about treatment outcomes were considered to be of higher 178 
quality. 179 
Limitations of previous reviews 180 
Reviewers identified a number of components of study design that make it difficult to draw 181 
comparisons between studies investigating treatment effect, including: definitions of 182 
10 
 
lymphedema; varied treatment protocols; protocols testing combination rather than individual  183 
treatments; and, lack of measurement of lymphedema-associated symptoms, impact on 184 
activities of daily living or quality of life. Differences in study protocols, results, conclusions 185 
and limitations are summarised in Table 4, according to each treatment type.  186 
Reviewers noted the variations in lymphedema definitions between studies, with some 187 
including people with self-reported lymphedema and others limiting study participation to 188 
those with specified limb size differences between affected and unaffected limbs. In addition, 189 
many different methods for measuring limb size and/or volume exist (e.g., limb 190 
circumferences, water displacement, perometry and tenometry) 11,22,24,31,38. The lack of data 191 
on lymphedema symptoms (apart from swelling) and quality of life was cited by reviewers as 192 
a limitation of the treatment efficacy research 35.  193 
Varied treatment protocols and bundling of interventions made it difficult for reviewers to 194 
discern the effect of individual treatment methods. Even within single treatment types, wide 195 
variations in prescriptions exist, partly due to the range of devices available (e.g., different 196 
levels of compression provided by garments, bandages and pumps). In many cases these 197 
limitations precluded reviewers from making firm conclusions about the benefit of treatment.  198 
The	effect	of	mainstream	treatments:	Definitions	of	treatment	types	199 
 200 
When possible, review findings have been grouped according to treatment type, as classified 201 
by the review authors. The treatment types included in each review are presented in Table 5. 202 
Where review authors did not group studies according to treatment types, findings were 203 
grouped according to the following definitions of treatments (adapted from A. L. Moseley, 204 
Carati, & Piller, 2007): 205 
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Complex Physical Therapy (CPT) – a period of intensive treatment or a treatment program 206 
involving at least two of the following: MLD, massage, compression bandaging, prescribed 207 
exercises.  208 
Manual Lymphatic Drainage (MLD) – light massage techniques applied by a health 209 
professional, to encourage removal of excess interstitial fluid, increase lymphatic transport 210 
and soften fibrotic induration. 211 
Self-massage – Similar massage techniques to MLD, applied by self or another person (e.g., 212 
partner). 213 
Laser therapy – low intensity wavelengths, either in a scanning or spot laser device.  214 
Pneumatic compression pump (PCP) – single- or multi-chambered pumps that envelop the 215 
limb, inflating and deflating with differing cycles and pressures.  216 
Compression bandaging (CB)– a gauze sleeve, soft cotton wrap or high-density foam and 2-3 217 
layers of short-stretch bandaging.  218 
Compression garments (CG) – compression sleeve or stocking with graduated pressure, from 219 
greatest compression at distal end of the limb to least compression at the proximal end.   220 
Prescribed exercises – progressive, resistive or sequential exercises prescribed with aim of 221 
varying total tissue pressure to encourage lymphatic drainage. 222 
Surgery – any surgical technique used to treat lymphedema. 223 
Other – all other treatment types, including pharmaceutical and dietary interventions, heat 224 
therapy, elevation, electrical stimulation, ultrasound, and CAM therapies.  225 
The	effect	of	mainstream	treatments:	Key	findings		226 
 227 
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A tabulated summary of review findings relating to each treatment type is presented in Table 228 
6. For each treatment, the conclusions made in each review were considered to reflect an 229 
improvement in lymphedema following treatment(‘yes’), no improvement in lymphedema 230 
(‘no’), or inconsistent results precluding any solid conclusions being made. When 231 
considering these findings alongside the strength of review protocols, there was no obvious 232 
explanation for the differences in the findings between reviews.  Thirteen different methods, 233 
scales and sets of guidelines were used by reviewers to assess methodological quality of their 234 
included studies, with some reviewers using multiple scales. Although there was variation in 235 
the assessment of study quality and reporting of study details, these discrepancies did not 236 
impact on the key findings reported between reviews, which are therefore reported here. 237 
The following key findings summarise the current available evidence that can be drawn from 238 
this critique of reviews: 239 
 There is agreement among reviews that CPT is effective at reducing limb volume. 240 
However, the most effective components of CPT cannot be identified based on the 241 
current level of evidence. Further, factors influencing the effect of treatment (i.e., 242 
leading to greater improvements in swelling and other symptoms) are not well 243 
understood. It appears ongoing therapy is required to maintain initial reductions 244 
achieved by an intensive period of CPT. 245 
 Reported effect of MLD on lymphedema is inconsistent. MLD appears to be 246 
effective when used with compression therapy, but the available evidence does not 247 
support its use as a stand-alone treatment strategy.  248 
 Limb volume reductions have been demonstrated following use of low-level laser 249 
therapy, but determining optimal dose and type (scanning versus spot) of laser 250 
therapy requires further investigation.  251 
13 
 
 Volume reductions have been achieved with the use of PCP, with greater 252 
reductions demonstrated when the use of pumps was combined with other 253 
treatments, including MLD, compression garments or self-administered massage.  254 
 Significant volume reductions have been demonstrated following the use of 255 
compression bandaging and garments in combined treatment programs, but the 256 
contribution of compression therapy alone, in reducing limb volume, is not well 257 
understood.   258 
 More evidence is needed to determine whether exercise contributes to volume 259 
reductions, and if so, whether reductions are maintained long term.  260 
 Use of surgical treatment for lymphedema has resulted in significant volume 261 
reductions, but has the potential for complications (including hematoma, skin 262 
necrosis, infection, deep vein thrombosis, loss of limb function and destruction of 263 
lymphatic vessels) and requires continued use of conservative treatment to 264 
maintain improvements.  265 
Discussion	266 
The aim of clinical practice guidelines is to improve health care delivery and health 267 
outcomes. Inconsistencies in guidelines can be frustrating and confusing to health 268 
professionals and patients. It is important to consider the strength of the evidence informing 269 
such guidelines, and also to recognise the limitations of the evidence when delivering health 270 
care to individuals. This critique examines the quality of the available evidence of 271 
lymphedema treatment effect, summarises the findings of previous reviews and makes 272 
recommendations for future research. Although the level of evidence does not enable firm 273 
conclusions to be drawn about the most effective individual treatments, the methodological 274 
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limitations identified in this critique highlight priorities to be addressed to further this field of 275 
research.  276 
The methodological quality of previous reviews has been variable, with differing levels of 277 
attention given to important aspects of study design. Review methodology varied too much 278 
for any quantitative scoring of the reviews to be appropriate. In addition, the overall quality 279 
of original studies investigating treatment for lymphedema has been poor, both in terms of 280 
study design and reporting. There is suggestion that the apparent lack of fundamental aspects 281 
of study design in some studies may be a result of poor reporting practices rather than 282 
inherent flaws in the research 22, but this cannot be assumed when the authors have not 283 
described methods adequately. The majority of studies have been cohort, case-control or 284 
cross-sectional studies, with few well-designed RCTs. Inconsistent methods for measuring 285 
lymphedema, multiple outcome assessors without inter-rater reliability assessment, lack of 286 
blinding, small samples, and lack of follow-up periods were among the methodological 287 
limitations. Conducting inappropriate data analyses and the reporting of unadjusted results 288 
were also evident in many studies, increasing the potential for biased results 10,11,36,37. These 289 
limitations of the majority of the studies included in previous reviews have led to 290 
underpowered results, a lack of generalisable findings and difficulties comparing results from 291 
studies of different treatments. 292 
Large, well-designed RCTs are needed to investigate treatments with inconsistent results 293 
(e.g., laser, MLD) as well as identify the essential individual components of combined 294 
treatment programs. These studies should aim to recruit sufficient numbers of participants to 295 
enable subgroup analyses (i.e., to determine whether particular treatments are more effective 296 
at treating upper-limb lymphedema compared with lower-limb lymphedema, or mild versus 297 
severe lymphedema). It has been suggested in several reviews that experimental interventions 298 
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should be compared to ‘standard lymphedema treatment’ 22, but it is evident from the wide 299 
range of treatment protocols in the reviewed studies that there is little consensus on what 300 
‘standard lymphedema treatment’ involves. In all studies, treatment protocols should be 301 
described in sufficient detail to enable replication in other study populations. Where blinding 302 
of participants and health professionals administering treatment is not possible due to the 303 
nature of the intervention, the blinding of the outcome assessors would at least strengthen 304 
study design.  305 
To date, the effect of treatment has been measured primarily using objective measures of 306 
limb volume and little attention has been given to subjective treatment outcomes 23. The 307 
limited research investigating the impact of treatment on symptoms and quality of life 308 
suggests some treatments (e.g., MLD and prescribed exercises) that do not show evidence of 309 
reducing limb size may improve important lymphedema symptoms, such as pain and 310 
heaviness 35,37.  People with lymphedema experience physical and psychosocial symptoms 311 
equally as distressing as swelling 23, and their comprehensive assessment should form part of 312 
future treatment protocols.  313 
Addressing the methodological issues described above in future research will further the field 314 
and improve the evidence base to support lymphedema treatment. It is also important for 315 
future reviewers to use a systematic process to consider all relevant aspects of study design, 316 
such as those developed by Cochrane Collaboration for assessing risk of bias in experimental 317 
studies21, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 318 
(PRISMA) guidelines 40. While it is recognised that clinical guidelines should be developed 319 
based on the best available evidence, such guidelines form only one aspect of clinical 320 
decision making. Treating health professionals need to consider individual responses to 321 
treatment and feasibility of continuing with treatment long term. Treatments found to 322 
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improve lymphedema symptoms in the research setting may require extensive self-323 
management to maintain improvements, and without consideration of the factors influencing 324 
patients’ adherence to treatment, the translation of such research findings into practice could 325 
be limited. Further, the chronic and complex nature of lymphedema means patients’ 326 
experiences of associated symptoms and impacts on quality of life may vary widely. In 327 
addition to treatment guidelines, patients’ preferences and values, health professionals’ values 328 
and experiences, and availability of resources, should be considered 19. 329 
Conclusion	330 
The efficacy of compression therapy alone, or combined with MLD, has been supported by 331 
RCTs 33,37 for the treatment of lymphedema, and should continue to be prescribed. There is 332 
also preliminary evidence of improvements in lymphedema and associated symptoms 333 
following a range of other treatments.  However, it seems plausible that different treatments 334 
are more appropriate for different stages and/or severity of lymphedema. Further, long-term 335 
outcomes of any treatment are likely to be influenced by patients’ adherence to prescribed 336 
treatments.  Therefore, until the scientific evidence of any particular type of lymphedema 337 
treatment improves, clinical practice guidelines should acknowledge the relative weakness of 338 
the scientific evidence and emphasise the importance of individualised-care, whereby 339 
objective response to a given treatment is considered in light of changes in self-reported 340 
symptoms, as well as the time, cost and effort involved in adhering to the treatment 341 
prescribed.  Lymphedema therapists should be encouraged to consider their clinical 342 
judgement alongside patient feedback and be willing to be flexible in their management of 343 
lymphedema.     344 
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